Exobiosphere has partnered with Voyager Technologies to send its automated miniaturized lab to the International Space Station (ISS) for conducting biotech research. The lab, designed to autonomously maintain organ cells and deliver therapeutics, aims to accelerate research on disease progression and therapeutic effectiveness in microgravity environments.
The key takeaway for a professional in space tech is Exobiosphere's development of the Orbital High-Throughput Screening Device, which enables autonomous biotech experiments in space. This technology has potential implications for accelerating disease research and therapeutic testing, offering a unique selling point to attract biotech firms and eventually Big Pharma. The integration with Voyager Technologies and ESA to conduct these experiments on ISS and Haven-1 demonstrates a strategic move towards expanding commercial space research capabilities.